PMV Pharmaceuticals Reports Promising Phase 2 Trial Results

PMV Pharmaceuticals ( (PMVP) ) has provided an update.

On September 10, 2025, PMV Pharmaceuticals announced interim data from their Phase 2 PYNNACLE trial of rezatapopt, showing promising efficacy and safety in treating solid tumors with the TP53 Y220C mutation. The data supports the potential for rezatapopt to address significant unmet medical needs in platinum-resistant or refractory ovarian cancer, with plans for a New Drug Application submission in early 2027, indicating a strategic advancement in PMV’s clinical development program.

The most recent analyst rating on (PMVP) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on PMV Pharmaceuticals stock, see the PMVP Stock Forecast page.

Spark’s Take on PMVP Stock

According to Spark, TipRanks’ AI Analyst, PMVP is a Underperform.

PMV Pharmaceuticals faces significant challenges typical of a biotech firm in the pre-commercialization phase, with no revenue and high R&D costs leading to negative financials. The strong cash position offers some financial flexibility, but the lack of revenue and ongoing losses are significant concerns. Technical indicators suggest a bearish trend, and valuation metrics reflect the company’s developmental stage. A path to commercialization is essential for improving financial health and investor confidence.

To see Spark’s full report on PMVP stock, click here.

More about PMV Pharmaceuticals

PMV Pharmaceuticals operates in the biotechnology industry, focusing on developing therapies targeting the p53 protein, a crucial tumor suppressor gene. Their lead product, rezatapopt, is a first-in-class investigational drug aimed at treating cancers with the TP53 Y220C mutation, which is prevalent in various solid tumors, including ovarian cancer.

Average Trading Volume: 374,354

Technical Sentiment Signal: Hold

Current Market Cap: $74.19M

See more insights into PMVP stock on TipRanks’ Stock Analysis page.